Chee Keong Yap - 13 Aug 2026 Form 4 Insider Report for BioNexus Gene Lab Corp (BGLC)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
14 Aug 2026, 17:19:45 UTC
Prior SEC filing
04 Oct 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Chee Keong Yap

Key filing fact

Chee Keong Yap filed Form 4 for BioNexus Gene Lab Corp (BGLC) on 14 Aug 2026.

Key facts

  • This page summarizes Chee Keong Yap's Form 4 filing for BioNexus Gene Lab Corp (BGLC).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 14 Aug 2026, 17:19.

Change

  • Previous filing in this sequence was filed on 04 Oct 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001994541 Primary reporting owner

Yap Chee Keong

Relationship
Director
Address
10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR, MALAYSIA
Signature
/s/ Chee Keong Yap
Signature date
14 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BGLC transaction

Common Shares

Award

Transaction value
Shares
+32,258
Change %
Price
Shares after
32,258
Date
13 Aug 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a fully vested Other Stock-Based Award of 32,258 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .